Clinical Trial Update: Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluating switching from a nevirapine-based regimen to once-daily rilpivirine/emtricitabine/tenofovir for HIV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• nevirapine-based regimen (nevirapine-based regimen)
• rilpivirine/emtricitabine/tenofovir (rilpivirine/emtricitabine/tenofovir)

Snippet

Sponsor: Philip Grant | Conditions: HIV | Phase 2, Phase 3 | Status: COMPLETED